within Pharmacolibrary.Drugs.ATC.V;

model V03AB17_1
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.729,
    Cl             = 4.75e-05,
    adminDuration  = 600,
    adminMass      = 260 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0009266666666666666,
    Tlag           = 600,            
    Vdp             = 0.0058,
    k12             = 3.9,
    k21             = 3.9
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V03AB17_1</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Methylthioninium chloride, also known as methylene blue, is a thiazine dye that has been used medically for methemoglobinemia, ifosfamide-induced encephalopathy, cyanide poisoning, and as a surgical dye. It is also being explored for use in neurodegenerative diseases, such as Alzheimer's disease. The drug is approved for use in several countries for specific indications, primarily methemoglobinemia.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults after single oral administration.</p><h4>References</h4><ol><li><p>Peter, C, et al., &amp; Lauterburg, BH (2000). Pharmacokinetics and organ distribution of intravenous and oral methylene blue. <i>European journal of clinical pharmacology</i> 56(3) 247–250. DOI:<a href=\"https://doi.org/10.1007/s002280000124\">10.1007/s002280000124</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10952480/\">https://pubmed.ncbi.nlm.nih.gov/10952480</a></p></li><li><p>Aeschlimann, C, et al., &amp; Cerny, T (1998). Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 26(9) 883–890. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9733667/\">https://pubmed.ncbi.nlm.nih.gov/9733667</a></p></li><li><p>Baddeley, TC, et al., &amp; Wischik, CM (2015). Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer&#x27;s disease. <i>The Journal of pharmacology and experimental therapeutics</i> 352(1) 110–118. DOI:<a href=\"https://doi.org/10.1124/jpet.114.219352\">10.1124/jpet.114.219352</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25320049/\">https://pubmed.ncbi.nlm.nih.gov/25320049</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V03AB17_1;
